Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00737100 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis
A Phase 2 study of Cystic Fibrosis, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 510
- Enrollment target
- 20
- Study locations
NCT00737100 is a Phase 2 study of Cystic Fibrosis that has completed, run by Boehringer Ingelheim. The registered enrollment target is 510 participants, above the 176-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (190% higher). The trial reports 20 study locations across 11 states.
The verdict
NCT00737100, a Phase 2 study of Cystic Fibrosis, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 510 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the effects of 12-week treatment with two doses of tiotropium bromide (2.5 mcg q.d. and 5 mcg q.d.) compared to placebo administered via the Respimat device on lung function in patients with Cystic Fibrosis. The selection of the optimal dose will be based on bronchodilator efficacy, safety evaluations and pharmacokinetic evaluations
Conditions Studied
Interventions
- DRUG Placebo Respimat
- DRUG Tiotropium bromide 5 mcg
- DRUG tiotropium bromide-low dose-2.5mcg
Study Locations (20)
Florida
- 205.339.023 Boehringer Ingelheim Investigational Site - Jacksonville
- 205.339.021 Boehringer Ingelheim Investigational Site - Miami
- 205.339.030 Boehringer Ingelheim Investigational Site - Orlando
- 205.339.031 Boehringer Ingelheim Investigational Site - Orlando
Indiana
- 205.339.014 Boehringer Ingelheim Investigational Site - Indianapolis
- 205.339.022 Boehringer Ingelheim Investigational Site - Indianapolis
- 205.339.013 Boehringer Ingelheim Investigational Site - South Bend
Michigan
- 205.339.017 Boehringer Ingelheim Investigational Site - Ann Arbor
- 205.339.025 Boehringer Ingelheim Investigational Site - Detroit
- 205.339.016 Boehringer Ingelheim Investigational Site - Grand Rapids
New Jersey
- 205.339.029 Boehringer Ingelheim Investigational Site - Long Branch
- 205.339.009 Boehringer Ingelheim Investigational Site - Morristown
Oklahoma
- 205.339.020 Boehringer Ingelheim Investigational Site - Oklahoma City
- 205.339.032 Boehringer Ingelheim Investigational Site - Oklahoma City
Arizona
- 205.339.006 Boehringer Ingelheim Investigational Site - Tucson
California
- 205.339.019 Boehringer Ingelheim Investigational Site - San Diego
Iowa
- 205.339.001 Boehringer Ingelheim Investigational Site - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00737100
The ClinicalTrials.gov registry entry for NCT00737100 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 176-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (190% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo Respimat is the first listed.
NCT00737100 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Indiana, Michigan.
Frequently Asked Questions
What is clinical trial NCT00737100 about?
NCT00737100 is a clinical study titled "Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis". This study evaluates the effects of 12-week treatment with two doses of tiotropium bromide (2.5 mcg q.d. and 5 mcg q.d.) compared to placebo administered via the Respimat device on lung function in patients with Cystic Fibrosis. The selection of the optimal dose will be based on bronchodilator effic...
What is the current status of trial NCT00737100?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 510 participants. The study started on 2008-09.
What conditions does trial NCT00737100 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT00737100?
The interventions under investigation include: Placebo Respimat (DRUG), Tiotropium bromide 5 mcg (DRUG), tiotropium bromide-low dose-2.5mcg (DRUG).
Who is sponsoring clinical trial NCT00737100?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00737100 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Indiana, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis
RECRUITING · Phase 2
-
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPL84 in Patients with Cystic Fibrosis
RECRUITING · Phase 2
-
GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance
RECRUITING · Phase 2
-
A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
RECRUITING · Phase 2
-
SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.